Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Olanzapine Stories

2009-01-15 09:57:00

HOUSTON, Jan. 15 /PRNewswire/ -- The $800 million settlement that Eli Lilly and Company (NYSE: LLY) has agreed to pay to settle civil False Claims Act charges related to allegedly false or fraudulent marketing, promotion and sale of its drug Zyprexa can be traced to the courageous stands taken by employee whistleblowers, according to the Berg & Androphy law firm. The company's settlement with the federal government, which also includes a guilty plea in a separate criminal action,...

2009-01-15 09:55:00

PHILADELPHIA, Jan. 15 /PRNewswire/ -- Eli Lilly and Company announced today it has agreed to plead guilty to criminal conduct and to pay more than 1.4 billion in criminal and civil fines, penalties and damages arising from allegations made in multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded health care programs in connection with its market practices for its blockbuster atypical antipsychotic, Zyprexa. The settlement is...

2009-01-15 09:53:00

Philadelphia Attorney Stephen Sheller's Whistleblower Clients Help Government Recover $1.4 Billion Record Settlement and Criminal Fine in Eli Lilly & Company Zyprexa(R) Marketing Case Lead Attorney Filed Complaint in 2003 Representing Six Whistleblowers PHILADELPHIA, Jan. 15 /PRNewswire-USNewswire/ -- Pharmaceutical giant Eli Lilly & Company ("Lilly") will pay federal and state governments more than $1.4 billion to remedy a wide-ranging, off-label marketing scheme for its...

2009-01-15 09:43:00

$515 Million Criminal Fine is Largest Individual Corporate Criminal Fine in History; Civil Settlement Up To $800 Million WASHINGTON, Jan. 15 /PRNewswire-USNewswire/ -- American pharmaceutical giant Eli Lilly and Company today agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration (FDA), the Department of Justice announced today. This resolution includes a criminal fine of $515 million, the largest ever in a...

2009-01-15 05:05:00

INDIANAPOLIS, Jan. 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has reached resolution with the United States Attorney for the Eastern District of Pennsylvania (EDPA) and the Office of Consumer Litigation of the Department of Justice regarding the previously-reported government investigation into the company's past U.S. marketing and promotional practices for the antipsychotic medication Zyprexa(R) (olanzapine). Lilly has been cooperating...

0f18ee4546ed1ae5aac9463338c03cf91
2009-01-15 08:20:00

The risk of suddenly dying from a heart problem has not diminished with newer anti-psychotic drugs. A study found both older and newer anti-psychotics had increased the risk of death when used to treat agitation, aggression, and delusions in elderly dementia patients. Researchers found older drugs had already been linked to an increased chance of sudden cardiac death. The new, federally funded study appears in Thursday's issue of the New England Journal of Medicine. Researchers examined a...

2009-01-14 17:03:00

ROCKVILLE, Md., Jan 14 /PRNewswire-USNewswire/ -- Patients ages 30 to 74 who took atypical antipsychotics such as risperidone (sold as Risperdal), quetiapine (Seroquel), olanzapine (Zyprexa) and clozapine (Clozaril) had a significantly higher risk of sudden death from cardiac arrhythmias and other cardiac causes than patients who did not take these medications, according to a new study funded by HHS' Agency for Healthcare Research and Quality. The risk of death increased with higher doses of...

2009-01-07 17:12:00

INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults. Lilly is continuing to work with the agency on the new drug application (NDA). The FDA does not require any additional clinical trials for the continued review of the NDA. Per the agency's...

2008-12-11 05:30:00

NEW YORK, Dec. 11 /PRNewswire-FirstCall/ -- -- Innovation and Patient-Centered Approach Expected to Drive Future Success -- Lilly Climbs into Top 10 Pharmaceutical Companies in Worldwide Sales and Is Fastest Growing in U.S. -- FIPNet Strategy Expands Global Reach and Improves R&D Productivity -- Company Aims to Reduce Cost of Bringing New Medicine to Market from $1.2 Billion to $800 Million by 2010. -- R&D Pipeline Boasts Unprecedented 59...

2008-11-13 09:00:07

Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the third quarter ended September 30, 2008. For the third quarter of 2008, Corcept reported a net loss of $5.6 million, or $0.11 per share, compared to a net loss of $3.4 million, or $0.09 per share, for the third quarter of 2007. For the first nine months of 2008, the company reported a net loss of $13.9 million, or $0.30 per share, compared to a net loss of $7.4 million, or $0.23 per share, for the same...